Vertex EVP sells 828 shares under 10b5-1 plan

Vertex Pharmaceuticals executive Joy Liu reported an open-market sale of company stock.

Rhea-AI Filing Summary

Vertex Pharmaceuticals executive Joy Liu reported an open-market sale of company stock. On July 1, 2026, she sold 828 shares of Vertex common stock at an average price of $502.71 per share.

After this transaction, Liu directly holds 19,131 Vertex shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan that she entered into on November 25, 2025, indicating the trades were scheduled in advance rather than timed at her discretion.

Insider Trade Summary 10b5-1

Net Seller: 828 shares

Net Sell 1 txn

Insider Liu Joy

Role EVP and Chief Legal Officer

Sold 828 shs ($416K)

Type	Security	Shares	Price	Value
Sale	Common Stock	828	$502.71	$416K

Holdings After Transaction: Common Stock — 19,131 shares (Direct)

Footnotes (1)

1. F1. Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025.

Key Figures

Shares sold: 828 shares Sale price per share: $502.71 per share Shares held after sale: 19,131 shares +3 more

6 metrics

Shares sold 828 shares Open-market sale on July 1, 2026

Sale price per share $502.71 per share Average price for July 1, 2026 sale

Shares held after sale 19,131 shares Direct ownership following the transaction

Form type Form 4 Insider transaction report for Joy Liu

Trading plan adoption date November 25, 2025 Rule 10b5-1 plan entry date cited in footnote

Transaction date July 1, 2026 Date of open-market sale

Key Terms

Rule 10b5-1, open-market sale, Form 4, Common Stock

4 terms

Rule 10b5-1 regulatory

"Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

open-market sale financial

"transaction_action is described as an open-market sale of Common Stock"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"Insider transaction is reported on Form 4 by Joy Liu"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Common Stock financial

"The security title for the transaction is listed as Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Vertex (VRTX) executive Joy Liu report?

Joy Liu reported an open-market sale of Vertex common stock. She sold 828 shares on July 1, 2026 at an average price of $502.71 per share, as disclosed in her Form 4 insider trading report.

How many Vertex (VRTX) shares did Joy Liu sell and at what price?

Joy Liu sold 828 shares of Vertex common stock at $502.71 per share. This open-market sale was reported on Form 4 and reflects a scheduled transaction under her company-approved Rule 10b5-1 trading plan.

How many Vertex (VRTX) shares does Joy Liu hold after this sale?

Following the sale, Joy Liu directly holds 19,131 shares of Vertex common stock. This post-transaction ownership figure is reported in the Form 4 and shows she retains a substantial ongoing equity stake in the company.

Was Joy Liu’s Vertex (VRTX) stock sale under a Rule 10b5-1 plan?

Yes. The filing states the transaction was made under a company-approved Rule 10b5-1 trading plan entered on November 25, 2025. Such plans pre-schedule trades, reducing the significance of timing decisions by the executive.

What role does Joy Liu hold at Vertex (VRTX) in this Form 4 filing?

Joy Liu is identified as Vertex’s Executive Vice President and Chief Legal Officer. Her officer status is disclosed in the Form 4, which reports her personal open-market sale of Vertex common stock under a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/06/2026 - 04:13 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Liu Joy

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MASSACHUSETTS 02210

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP and Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2026		S(1)		828	D	$502.71	19,131	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	07/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)